灯盏花素联合低分子肝素钙治疗对进展性脑梗死ET⁃1、sTM及CEC水平变化的影响  

Effect of breviscapine combined with low molecular weight heparin calcium therapy on the changes of ET⁃1,sTM and CEC levels in patients with progressive cerebral infarction

作　　者：张建丽[1] 张霞[2] ZHANG Jianli;ZHANG Xia(Medical Teaching and Research Office,Nanyang Road,the Second Affiliated Hospital of Zhengzhou University,Zhengzhou,Henan,China,450000;Department of Neurology,Nanyang Road,the Second Affiliated Hospital of Zhengzhou University,Zhengzhou,Henan,China,450000)

机构地区：[1]郑州大学第二附属医院南阳路院区医教研办公室,河南郑州450000 [2]郑州大学第二附属医院南阳路院区神经内科,河南郑州450000

出　　处：《分子诊断与治疗杂志》2023年第5期751-754,共4页Journal of Molecular Diagnostics and Therapy

基　　金：河南省医学科技攻关计划联合共建项目(LHGJ20190017)。

摘　　要：目的探讨灯盏花素联合低分子肝素钙治疗对进展性脑梗死内皮缩血管肽(ET⁃1)、血栓调节蛋白(sTM)及循环内皮细胞(CEC)水平变化的影响。方法选取2019年6月至2021年12月期间于郑州大学第二附属医院南阳路院区就诊的123例进展性脑梗死患者,根据治疗方式将其分为对照组(61例,低分子肝素钙治疗)和观察组(62例,灯盏花素联合低分子肝素钙),观察两组治疗前、治疗14 d后的内皮缩血管肽⁃1(ET⁃1)、循环内皮细胞(CEC)、血栓调节蛋白(sTM)水平以及美国国立卫生院卒中量表(NIHSS)和日常生活活动能力(ADL)、临床疗效及不良反应。结果观察组治疗总有效率为96.77%,高于对照组的73.77%,差异有统计学意义(P<0.05);观察组血清ET⁃1、sTM及CEC水平低于对照组,差异有统计学意义(P<0.05);观察组NIHSS评分低于对照组、ADL评分高于对照组,差异有统计学意义(P<0.05);对照组不良反应发生率为6.56%,稍低于观察组的9.68%,两组不良反应比较差异无统计学意义(P>0.05)。结论进展行脑梗死患者使用灯盏花素联合低分子肝素钙治疗能降低脑血管ET⁃1、sTM及CEC水平,改善患者神经功能及日常生活能力,且具有较高的安全性,值得临床广泛应用。Objective To investigate the effect of breviscapine combined with low molecular weight heparin calcium therapy on the changes of ET⁃1,sTM and CEC levels in progressive cerebral infarction.Methods A total of 123 patients with progressive cerebral infarction who visited the Nanyang Road Campus of the Second Affiliated Hospital of Zhengzhou University from June 2019 to December 2021 were selected,and according to the treatment methods,they were divided into the control group(61 cases,treated with low molecular weight heparin calcium)and the observation group(62 cases,breviscapine combined with low molecular weight heparin calcium),The levels of endothelin(ET⁃1),circulating endothelial cells(CEC)and soluble thrombomodulin(sTM)between the two groups before treatment and after 14 days of treatment were observed.National Institutes of Health Stroke Scale(NIHSS)and activities of daily living(ADL),clinical efficacy and adverse reactions were compared.Results The total effective rate of treatment in the observation group was 96.77%,which was significantly higher than that in the control group(73.77%),and the difference was statistically significant(P<0.05).The serum levels of ET⁃1,sTM and CEC in the observation group were lower than those in the control group,and the difference was statistically significant(P<0.05).The NIHSS score in the observation group was lower than that in the control group,and the ADL score was higher than that in the control group,with statistical significance(P<0.05).The incidence of adverse reactions in the control group was 6.56%,which was slightly lower than that in the observation group,which was 9.68%,and there was no statistical significance in the comparison of adverse reactions between the two groups(P>0.05).Conclusion he treatment of breviscapine combined with low molecular weight heparin calcium in patients with progressive cerebral infarction can reduce the levels of cerebrovascular ET⁃1,sTM and CEC,improve the neurological function and daily living ability of patients,and has hi

关 键 词：灯盏花素 低分子肝素钙 进展性脑梗死 

分 类 号：R743.3[医药卫生—神经病学与精神病学]